Search

everythinglearnresearchcommunity

for

Search:↓

RU58841's legitimacy and sourcing concerns. Users suggest caution and recommend trusted sources over platforms like Amazon.

The conversation is about finding a legitimate source for RU58841 in Germany, with suggestions including Receptorchem and GeneTherica. Anageninc and Chemyo do not deliver to Germany.

A user is seeking advice on purchasing RU58841 with Minoxidil in Canada and is concerned about the vehicle used for the solution. They also inquire about the differences between RU58841 and topical finasteride in terms of efficacy.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

A 35-year-old man shares his one-year progress using 1.25 mg oral finasteride and 5% topical minoxidil for hair loss, with no side effects and slight improvement in his front hairline. He also uses keto shampoo twice a week and a 0.5mm roller weekly.

User asks how long RU58841 bottle lasts, inquires about application, quantities, and mixing at home.

A 19-year-old trans man has been using Finasteride 1mg for a little over two months and is concerned about worsening hair loss, noting a fuzzy and soft hairline and crown. The user is upset as the hair loss appears worse than before starting the treatment.

Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.

The user has been taking 0.25mg of oral finasteride daily for a month and is considering increasing the dose to 1/3 of a pill. They have also been using topical minoxidil for several years.

The conversation is about hair loss and the use of specific treatments like minoxidil, finasteride, and RU58841.

France is considering reviewing finasteride and dutasteride due to concerns about their safety, but a ban in the EU is unlikely due to regulatory hurdles. Many users express frustration over the potential ban, emphasizing the effectiveness of finasteride for hair loss and criticizing the influence of anecdotal evidence on public health policy.

Actifolic's RU58841 and Pyri products are perceived as ineffective, with users reporting no side effects or improvements, suggesting possible quality issues. Users recommend alternative sources and emphasize the importance of timing when using RU58841 with Minoxidil.

A 43-year-old is experiencing hair thinning and is considering hair loss treatments. They are hesitant to use topical Minoxidil due to its toxicity to pets and oral Finasteride due to concerns about side effects, and are exploring alternatives like topical Finasteride, oral Minoxidil, or microneedling.

A 37-year-old is starting minoxidil and finasteride to address hair thinning. They are hopeful for positive results after seeing others' success.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

A 49-year-old man has been using 1 mg of finasteride daily and microneedling weekly for four months to address hair loss, with no side effects and noticeable progress. He shares his experience and encourages others to consider treatment options without fear.

User discusses group buy for finerenone, a third-gen mineralocorticoid antagonist for hair loss treatment. Finerenone inhibits TGFb, NOX, and ROS, and improves renal and cardiac function; topical dose should be no more than 10mg per day.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

Making a hair solution using RU58841 from raw powder. Users humorously compare the process to a science experiment.

The conversation is about sourcing raw minoxidil and finasteride powder to mix with RU58841 for hair loss treatment. It warns against using raw minoxidil due to safety concerns.

The user experienced microinflammation on the crown after using mometasone furoate (Nasonex) nasal spray. They are seeking information on the relationship between this corticosteroid and hair loss.

A 42-year-old user shared positive results from using oral and topical Minoxidil, Finasteride, and weekly dermarolling for hair regrowth over three months. The community responded positively, noting significant progress and discussing treatment details and concerns.

PP405 is suspected to be a scam, with users doubting its legitimacy and effectiveness. Many recommend using proven treatments like finasteride and minoxidil.

A 33-year-old man shares his positive hair regrowth results using 1mg finasteride daily, 5% topical minoxidil twice daily, and a 0.5mm dermaroller weekly. He feels more confident and encourages others to try the routine despite potential side effects.

OP mixed RU58841 with minoxidil and noticed undissolved particles. They are seeking advice on whether it matters or how to fully dissolve it.

The user is taking a 2-in-1 pill containing 1mg finasteride and 3mg minoxidil daily, noticing some hair thickening and new hair growth but minimal progress at the back of the head. They are considering adding topical minoxidil or increasing dosage and are unsure if they should change their routine or wait for more results.

IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.

RU-58841 does not dissolve well in common Minoxidil solutions due to water content, requiring a 70/30 ethanol/propylene glycol mix. Users report using separate solutions for RU-58841 and finasteride/Minoxidil for better results.

CB-03-01, also known as Breezula, is being considered as an alternative to DHT blockers for hair loss. Users are discussing its effectiveness, potential regrowth, side effects like scalp irritation, and hormonal impacts.

The conversation discusses using RU58841 mixed with topical minoxidil for hair loss, noting its chemical instability and storage challenges. A user shares their experience using RU58841 with ethanol and propylene glycol, mentioning no significant results yet.